FC Barcelona forms long-term partnership with Hungarian brand BioTechUSA

FC Barcelona has entered into a multi-year partnership with BioTechUSA, a Hungarian-owned family business specialising in sports supplements. Under this agreement, the company will supply its range of nutritional products—including proteins, vitamins, and recovery supplements—to Barcelona players like Lamine Yamal, Pedri, Dani Olmo, and other top athletes at the club. This collaboration extends beyond product supply, focusing also on research, education, and knowledge transfer, suggesting deeper potential for the partnership.

A historic partnership: Barcelona and BioTechUSA

The deal was formalised before Barcelona’s La Liga match against Real Valladolid, with Juli Guiu, FC Barcelona’s Vice President of Marketing, and BioTechUSA co-owners Bálint and Balázs Lévai present, Index reports. According to Guiu, quality nutrition and well-planned supplementation play a crucial role in player performance, and Barcelona views this partnership with BioTechUSA as a guarantee of top-level support in this area.

Bálint Lévai emphasised that Barcelona carefully selects its global partners, adding that BioTechUSA’s premium-quality products and expertise exceeded the club’s expectations. The two parties share common values and philosophies, making the collaboration a natural fit from the outset.

The announcement coincided with Barcelona’s dominant 7-0 victory against Valladolid at the Olympic Stadium, as the Camp Nou undergoes renovation. Despite the ongoing construction, the partnership launch took place against the backdrop of Barcelona’s rich sporting history and future promise, symbolised by young stars like Lamine Yamal, who represent the next generation of the club’s excellence.

History of BioTechUSA

BioTechUSA, founded in Hungary over 30 years ago, has grown into one of Europe’s largest producers and distributors of dietary supplements, with a presence in 103 countries, 49 webshops, 322 franchise stores, and over 4,500 B2B partners. Even amid economic challenges, the company achieved a nearly 15% increase in revenue in 2023, reaching HUF 90.49 billion (about EUR 230 million). Their EBITDA also rose by 3.5% to EUR 10.47 billion (about EUR 26.6 million), and the company invested nearly HUF 5 billion (EUR 12.7 million) in new products and development.